新诊断T2MD格列吡嗪联合甘精胰岛素强化治疗的研究

Newly Diagnosed Type 2 Diabetes Glipizide and Insulin Aspart Joint Insulin Glargine Intensive Therapy Research

目的观察新诊断2型糖尿病患者采用格列吡嗪和门冬胰岛素分别联合甘精胰岛素强化治疗的有效性、安全性及性价比。方法整群选取2013年2月—2014年12月在该院住院治疗的82例T2DM患者随机分为格列吡嗪联合甘精胰岛素(A组)和门冬胰岛素联合甘精胰岛素(B组),治疗两周后复查患者FBG、2 hBG、FC-P、2 hC-P、血糖达标时间、低血糖发生率及药品费用。结果 2周后,两组FBG、2 hBG、较治疗前明显下降,FC-P、2 hC-P较治疗前明显升高(P<0.05);低血糖发生率A组为2.2%,B组为5.2%,血糖达标时间A组稍长,以上2个指标两组差异无统计学意义(P>0.05);两组治疗费用A组明显低于B组,差异有统计学意义(P<0.01)。结论对于新诊断T2DM患者,格列吡嗪联合甘精胰岛素强化治疗,可很好的控制血糖,改善T2DM患者的胰岛β细胞功能,控制血糖疗效与门冬胰岛素联合甘精胰岛素治疗相当,但前者费用更少,更方便。

Objective To observe the newly diagnosed T2 DM patients with Glipizide and Insulin aspart combined respectively with Insulin glargine intensification effectiveness, safety and cost of treatment. Methods 82 cases of T2 DM were randomly divided into Glipizide combined with Insulin glargine(group A) and Insulin aspart Insulin glargine(group B), treatment for two weeks. Results After two weeks, two groups of FBG, 2 h BG, was significantly lower than that before treatment, FC-P, 2 h C-P significantly after treatment(P<0.05); the incidence of hypoglycemia in A group was 2.2%, 5.2% in B group, blood glucose time slightly longer in group A, no significant difference between two groups(above two indexes P>0.05); two groups of treatment cost was lower in group A than in group B, the difference was statistically significant(P<0.01). Conclusion For patients with newly diagnosed T2 DM, Glipizide combined with Glargine insulin intensive treatment, can control blood glucose well, improve the islet beta cell function in patients with T2 DM, and the effect of Insulin aspart Insulin glargine quite, but the former costs less, more convenient.